Mammalian Cell Culture to COVID-19 Vaccine Adjuvant in 3 weeks
Challenge from the Client
The initial scope of this project was to design new manufacturing suites for mammalian cell culture and purification, in two phases. Soon after the COVID-19 outbreak, our client entered into an agreement with an international vaccine development company and there was a quick shift in direction.
Our Approach & Solution
The client asked to redesign the ISO-7 cleanrooms to accommodate a new layout for new equipment intended for vaccine adjuvant manufacturing while maintaining the original design for an eventual return mammalian cell culture. This meant adding new utilities on top of previously existing phases 1 and 2 for mammalian cell culture, and now phase 3 with the new partner.
Our design team engaged quickly and collaborated efficiently to support our client from the initial concept, as defining the equipment list, up to the final construction drawing. Since the project was so fast-paced, most of the equipment used had to be shipped to the United States from existing facilities across the globe. This meant different power requirements and European units. Frequent changes from equipment availability and LT changes required almost daily communication and a continuous uninterrupted flow of information between all project stakeholders.
The Results
IPS delivered the drawings within three short weeks. Starting from a kick-off meeting with the client and defining equipment layout, to issuing drawings to the builder. Additionally, we worked with the local government to ensure permits were updated maintained. The client was very happy with the performance of the IPS team and this project served as an example that IPS is fully capable deliver complex projects within promised constraints.
Related Molecules
Antibody Drug Conjugation Commercial Manufacturing
Read MoreApplied first class design tools and industry specific experiences to develop a greenfield site for commercial ADC manufacturing.
Annex 1 - The Brave New World of Aseptic Regulatory Compliance
Read MoreAfter six years in review, the final emergence of Annex 1 in August 2022 has either been a consolidation of accepted practice and wisdom, or a rude awakening for many!
Large-Scale Bulk Manufacturing Facility
Read MoreIPS built a new greenfield facility in Ireland for bulk biologics manufacturing with single-use technology under an extremely aggressive timeline.
Single-Use Mammalian Cell Culture Facility - Vial to Vial
Read MoreOur challenge was to design a biologics manufacturing launch facility within an existing shell & office building.
Fast-Track Project Delivery Model
Read MoreA vaccine manufacturer and distributor needed IPS’ expertise to meet an aggressive timeline for expansion of their production facility.
Detailed Process Piping
Read MoreSupporting a client’s dynamic business requirements to produce a near-fabrication-level model to reduce schedule time.
Water For Injection (WFI) Generation System Design for a Global CMO Biotechnology Facility for the Manufacture of mAb/Recombinant Protein
Read MoreBiotech CMO client needed an n+1 redundant system to handle increased WFI demand, while reducing operating costs.
Commercial Manufacturing of Autologous Muscle Derived Cell (AMDC) products
Read MoreApplying industry-leading knowledge and expertise to support CGMP-compliant manufacturing process scale-up.
Clinical Phage Production - Design/Build/Qualify
Read MoreA start-up biotech company needed to generate phase 1 and phase 2 clinical material for a phage-based therapy on an aggressive timeline and tight budget.
Largest Single-use Based mAb Facility in the World
Read MoreOur CMO client wanted to do something radically different by creating a multiproduct, multiscale mAb facility that could flex upstream capacity in 2000L intervals.
CQV: A Human Challenge
Read MoreEMEA experts overcame a client's planning challenges to create a cohesive team and take ownership of the project
Modular Design, Construction and Installation of QC Labs
Read MoreA copy/paste modular build from the UK to Spain that overcame hurdles from the UK’s decision to leave the European Union.
Animal Healthcare Business and Engineering Alignment
Read MoreCMO client needed to increase production capacity to meet projected demand of their animal healthcare product.
Mobile Modular Vaccine Facility
Read MoreDeliver a modular vaccine facility capable of being relocated anywhere in the world with minimal host facility requirements.
Delivering a New Building with Two Project Teams
Read MoreProvided a client and building tenant with construction management services for the interior fit-out of a new 50,000sf pharmaceutical testing facility while a separate vendor constructs the core & shell for the landlord.
Gene Therapy Facility
Read MoreOur client needed an efficient design for their gene biologics plant within an existing building with limited space for air handlers and mechanical equipment.
Clinical CAR-T Capabilities
Read MoreA global biopharmaceutical manufacturer chose iCON to expedite its CAR-T therapy production timeline.
Clinical Lentivirus/AAV Manufacturing Facility
Read MoreA fast-tracked execution strategy for gene therapy manufacturing requiring “out of the box” thinking.
Site Selection for an Advanced Gene Therapy Company
Read MoreOur client was looking for a new site for their 2000L scale gene therapy manufacturing facility in a very saturated real estate market.
